Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)

Patients with chronic lymphocytic leukemia (CLL) have benefited from the introduction of targeted therapy for leukemia. Rituximab (a chimeric murine-derived monoclonal antibody that targets CD20 on lymphocytes) was the first monoclonal antibody to affect the natural course of this disease. Several r...

Full description

Saved in:
Bibliographic Details
Main Authors: Al-Kali, Aref, Wierda, William, Keating, Michael, O’Brien, Susan
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2010
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3262335/
https://ncbi.nlm.nih.gov/pubmed/22282690
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items